THE SCIENCE. THE BUSINESS. THE WORLD OF BIOPHARMACEUTICALS.

2005 MEDIA PLANNER www.biopharminternational.com THE PRINT-BASED MARKETING Display Advertising BIOPHARM The foundation of any b-to-b marketing program, print advertising allows you to BRAND touch 29,200 BPA-qualified subscribers* with your brand or product message. BioPharm International’s Build your marketing plan around the message portfolio of products allows conveyed in your print ad and utilize other channels you to reach our highly to further reinforce your message. desirable audience through multiple marketing channels. Custom Publishing Work with us to write and design a custom white paper or article Studies show integrated published as an advertorial in the pages of BioPharm. marketing is the key to successfully delivering your Insert A unique way to deliver white papers, brochures or any other collateral message to today’s buyer. material to our readers. Reinforce your message to the most important audience Polybag in your market—ask your Talk about premium placement! Send your printed piece as a ride-along advertising sales manager and readers will get the message as soon as the issue hits their desk. to design an integrated program Direct Mail utilizing the channels that best Planning a direct mail campaign to reinforce your ad message? meet your marketing objectives. Rent our list to ensure your marketing material reaches your most important audience.

Post-It Note A truly unique way to send your message to our readers, Post-It Notes serve as front cover reminders about your brand. Use Post-Its to call out your ads in the issue or run 6 or 12 Post-It Notes for a truly unique campaign.

Business Reply Card An efficient and effective direct response medium, BRCs can be used to promote a contest or simply to provide our readers with a distinct opportunity to contact you for more information.

* BPA June 2004 WEB-BASED MARKETING

Web Site There are many opportunities on biopharminternational.com. Banners, buttons, skyscrapers, big-box ads, product spotlights, and QuickPolls all provide unique ways for sellers to connect with buyers online.

Webinar Work with us to create an on-line event that will help you address key industry issues among the people who are key to the industry.

Flash Presentation Another dynamic way to send your marketing message to our audience. Capture the attention of our readers within this exciting presentation tool.

MarketPulse Allow us to deliver the answers to your most pressing questions with a customized on-line survey of our readers.

ProductBlast You provide the links and the message and we provide the community. Blast your product offerings, on-line catalog or announce your newest products with ProductBlast. Sent to 5,000 select readers, based on your demographic target, BioPharm International is ProductBlast is an effective way to spread the word about your products, and the #1 brand devoted to the directly link readers to them. science, strategies & trends E-Newsletter Content-driven newsletters offer a unique opportunity to surround your shaping the global landscape advertisement with content relevant to your brand, and route buyers to a for biotherapeutics. page on your site specific to your message. BioPharm’s focus FACE-TO-FACE MARKETING on the applied technologies

Conferences utilized in biopharmaceutical Advanstar’s Pharmaceutical & Science Group conferences provide top industry development and its focus on gatherings for up-to-the minute information and unmatched opportunity to interact with biopharm/pharmaceutical industry executives. Under this umbrella, the business forces driving The Institute for Validation Technology (IVT) and Pharmaceutical Executive that growth have attracted produced successful conferences on a variety of topics relevant to your market. Ask your sales manager how you can leverage your sponsorship budget at a BPA-qualified, global one of our 2005 conferences. audience of 29,200.* Single-Sponsored Event Do you have an idea for a conference but lack the resources to bring your target community together? Partner with us to launch a conference focused on your objectives.

Reader Roundtable You provide the topic, and we will provide a roundtable of readers selected from your target demographic, and facilitate your meeting. Think of it as your very own expert focus group. 29,200 BPA-QUALIFIED SUBSCRIBERS IN THE CIRCULATION BUSINESSES AND FUNCTIONS YOU NEED TO REACH* BioPharm International delivers a targeted audience of INDUSTRY^ professionals involved in all Biopharmaceuticals/Biologics, Classical 49.8% stages of the development and Pharmaceutical Manufacturing (14,534) manufacture of biopharmaceutical Biotech/Biopharm Research (2,479) 8.5% therapeutics and diagnostics. Biopharmaceutical/Biologics Process Development, 7.5% Biodiagnostic Process Development (2,957) Research Institutes/Universities/Colleges (2,171) 7.4% Contract Research/Analytical Services (2,000) 6.8% Business/Investment/Legal Services (1,087) 3.7% Architecture/Engineering Construction (1,008) 3.5% Government (894) 3.1% Biodiagnostic Manufacturing (811) 2.8% Specialty or Bulk Chemical Manufacturing, 2.8% Bulk Products and Raw Materials Producers (828) Biotherapeutic Discovery/Development (667) 2.3% Biopharm Formulation/Delivery (511) 1.8% Transgenic Therapeutic Productions (53) .02%

JOB FUNCTION^

Research & Development (7,607) 26.1%

Quality Assurance/Control,Validation/ 22.2% Regulatory/Clinical Affairs (6,471) Corporate Management/Business Advisor (4,409) 15.1% Production/Manufacturing (2,771) 9.5% Process Development (2,234) 7.7% Tech Services/ 6.1% Analytical Development Support (1,775) Project Management (1,478) 5.1% Lab Management (1,189) 4.1% Plant/Project Engineering/Facility Design (1,040) 3.6% Technology Transfer (314) 1.0% Materials Management/Purchasing (272) 0.9%

* BPA International Statement June 2004 ^ Publisher’s Own Data BioPharm International delivers access to the top public biotech companies as well as the industry’s top pharmaceutical companies that are heavily entrenched in biopharmaceutical research & development.

REACH THE TOP 100# AND THE TOP PHARMA COMPANIES PUBLIC BIOTECH COMPANIES... HOLDING A MAJOR STAKE IN BIOTECHNOLOGY^

AMGEN AFFYMETRIX # of subscribers GENENTECH CURAGEN Pfizer ..... 809 BIO GEN DECODE GENETICS Wyeth ..... 657 MILLENIUM ACTELION Abbott ..... 472 CHIRON GENMAB Merck ..... 452 GENZME XOMA Sanofi-Aventis ..... 437 MONSANTO MAXYGEN GlaxoSmithKline ..... 423 ELAN ADOLOR Eli Lilly ..... 381 SEPRACOR BIOMARIN Baxter International ..... 289 SHIRE INVITROGEN Hoffmann La-Roche ..... 286 VERTEX PHARM INC CUBIST Bristol-Myers Squibb ..... 280 CELLTECH CERUS Bayer ..... 265 HUMAN GENOME SCIENCE ANDRX Schering Plough ..... 242 NEUROCRINE KOS Johnson & Johnson ..... 221 CEPHALON ENDO Centocor ..... 161 GILEAD ARENA Astra/Zeneca ..... 158 MED IMMUNE MGI Novartis ..... 145 AMYLIN ARADIGM Boehringer Ingelheim ..... 122 REGENERON ILEX ONCOLOGY Cardinal Health ..... 105 NEKTAR VERNALIS Dow ..... 94 EXELIXIS ANTIGENICS Diosynth ..... 86 TULARIK MYRIAD Medimmune ..... 77 CELGENE ATHEROGENICS INC Alza ..... 76 IMCLONE RIGEL Novo Nordisk ..... 74 CELERA GPC BIO Watson Pharmaceuticals ..... 70 INTERMUNE QLT INC Allergan ..... 69 NPS MAXIM Quintiles ..... 69 ISIS TELIK 3M ..... 65 INCYTE PRAECIS Lonza ..... 64 OSI SYMYX IDEC ..... 64 ABGENIX BRUKER PPD Inc ..... 64 CORIXA DENDREON Millipore ..... 62 MEDAREX MYOGEN Solvay ..... 60 CELL THERAPUETICS TRIMERIS Amersham ..... 58 CELL GENESYS KOSAN Alcon ..... 58 GENTA ATRIX Proctor & Gamble ..... 58 PROTEIN DESIGN LAB ACAMBIS Organon ..... 56 LEXICON MEDICINES COMPANY Sigma Aldrich ..... 52 CAMBRIDGE ANTIBODY CALIPER TECH CV THERAPEUTICS UNITED THERAPEUTICS VICURON NEOPHARM INC PHARMACEUTICAL PRODUCT ONYX DEVELOP GUILDFORD TRANSKARYOTIC THERAPIES AETERNA DIVERSA NEUROGEN GENENCOR LA JOLLA ZYMOGENETICS IDEXX ALEXION QIAGEN LIGAND INNOGENETICS ALKERMES NUVELO AND SAVIENT

* BPA June 2004 ^ Publisher’s Own Data # Parexel, Nature Biotechnology, June 2003 MONTHLY COLUMNS EDITORIAL Regulatory Beat — Jill Wechsler, our veteran Washington editor, provides up-to-the-minute For 18 years, coverage of FDA, CBER, CDER, and Congressional BioPharm International has been committee meetings, reporting on regulatory the biopharmaceutical industry’s decisions, policy developments, and trends that magazine of choice, providing may influence the biopharm industry. peer-reviewed, action-oriented StreetTalk — StreetTalk offers critical analyses information on every aspect of the industry's key issues and strategies, companies and top of the industry, from science and executives, technology and trends from the Wall Street perspective. technology to regulatory Editor Brian J. O'Connell is a well-known author and expert and business issues. business/ finance commentator for CNN and Fox News. BioPharm International: Applications — What is the latest technology available to researchers, developers and manufacturers? Each column features a different application that has been developed to The science, the business, the help industry achieve improved results, whether in the lab or on the production line. world of biopharmaceuticals. Authors vary every month, representing a variety of companies in both the US and abroad.

ROTATING COLUMNS Outsourcing — It’s a tall order for any company—even the largest—to excel in every facet of the biopharma-ceutical field. Biopharms that devote their efforts to core functionalities rely, instead, on outsourcing expertise, whether it be IT, research, development, manufac- turing, clinical trials, marketing or distribution. Consequently, this column offers useful insight about outsourcing strategies and recent alliances, along with trend analyses and short-term forecasting. Operations Excellence — Patent expirations, generics, counterfeit drugs, Medicare, and pricing – the pressure to streamline operations remains high. This column features different strategies for improving operational efficiency and effectiveness, including a quarterly update from Tefen’s Amir London, who will share the progress achieved by pharma and CMO members of the Operations Excellence Consortium, which now meets on both US coasts and Europe. Compliance Briefing — When it comes to the ever-evolving world of compliance, companies need all the help they can get. From processes to equipment to documentation, Compliance Briefing offers actionable advice to keep biopharms and labs ahead of the regulatory curve and their operations at peak performance. BioPartnering — These days, partnerships can be found in all aspects of the drug development process: research and development, manufacturing, clinical trials. But, not all partnerships succeed. This column offers expert advice from those who have succeeded in both domestic and global relationships, addressing the individual elements – both simple and complex – that can make or break a business alliance. Career Development — By special reader request, BioPharm is bringing back a career column to cover a variety of employment and career issues that are typically found in the workplace for life science professionals.

Nobody covers the business of biopharmaceuticals like BioPharm International. At a glance, here’s our department and topic coverage planned for 2005:

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Operations Excellence Y Y Y Y BioPartnerships Y Y Y Y Y Y Regulatory Beat Y Y Y Y Y Y Y Y Y Y Y Y Outsourcing Y Y Y Y Site Expansion Y Y Y Y StreetTalk Y Y Y Y Y Y Y Y Y Y Y Y Compliance Briefing Y Y Y Y Y SPECIAL SUPPLEMENTS

ISSUES BUYERS GUIDE & DIRECTORY Published in April Back in 2005, the Buyers Guide and Directory will continue to be indispensable to buyers and sellers of biopharmaceutical products and services. Reach readers interested in finding the companies, partners and services that will help them successfully deliver new drugs to market—include your company, product or service through display advertising, enhanced listings, logo placement or list your latest application note in the special Application Notebook section.

BIOPARTNERSHIPS: Strategic Alliances To Accelerate Drug Development Published in October To help pharma and biotech leaders respond to the ever-changing challenges of creative, profitable partnerships, the editors of Pharmaceutical Executive and BioPharm International—industry-leading publications in their respective fields— have assembled a unique information resource for executives, featuring up-to-the-minute analysis, hands-on-advice, and behind-the-scenes insight from top pharma and biotech professionals and leading consultants. Ask your advertising sales manager about this issue’s extended circulation and unique value-added opportunities.

PRIMERS

A GUIDE TO VALIDATION Published in March Validation procedures and their documentation are an integral part of a Good Manufacturing Practices program; a general discussion of equipment, process and product validation elements that enable compliance with FDA expectations.

A GUIDE TO ANALYTICAL ADVANCES Published in September An examination of the newest technologies and test methods, including guidelines (Q2A, Q2B, USP 27) and supplemental recommendations for the development, optimization and validation of biopharmaceuticals.

A GUIDE TO INTELLECTUAL PROPERTY (IP) Published in June Inspired by the growing interest in outside alliances; knowing how to identify, qualify, and protect intellectual property is an important critical part of any biopharm business strategy. This primer will outline the history and importance of IP and provide useful tips and case studies to help companies make critical decisions during all phases of product development. BIOPHARM INTERNATIONAL EDITORIAL CALENDAR 2005

JANUARY Closes December 3 FEBRUARY Closes January 4

FEATURED EDITORIAL: FEATURED EDITORIAL: Separation & Purification; Chromatography; Contract Services & Outsourcing; Facilities Management; Compliance/Regulatory (e-solutions); Protein Engineering Systems Integration; Site Expansion: Canada

BONUS DISTRIBUTION: BONUS DISTRIBUTION: PepTalk, Informex, Phacilitate Cell & Gene Therapy Forum Pittcon

ADDED VALUE: ADDED VALUE: Free 4C Product/Literature Release Free 4C Product/Literature Release

AD MATERIALS DUE: AD MATERIALS DUE: December 9 January 10

EDITORIAL MANUSCRIPT DUE: EDITORIAL MANUSCRIPT DUE: October 8 November 5

MAY Closes April 1 JUNE Closes May 1

FEATURED EDITORIAL: FEATURED EDITORIAL: Fermentation & Cell Culture; Raw Materials; Plant-made Pharma; Outsourcing: CROs; Good Laboratory Practices (GLP); Facilities Management Separation & Purification; Raising Capital

ANNUAL RESOURCE: PRIMER: A Guide to Intellectual Property (IP) Directory/Buyer's Guide BONUS DISTRIBUTION: BIO 2005, ADDED VALUE: DIA. AAPS-National Biotechnology Conference Free 4C Product/Literature Release ADDED VALUE: AD MATERIALS DUE: Full Page Advertisers Receive BIO Exhibitor ProductBlast April 7 Literature Pack at BIO 2005, FREE Ad Laminate for Show Advertisers

EDITORIAL MANUSCRIPT DUE: AD MATERIALS DUE: May 7 February 4 EDITORIAL MANUSCRIPT DUE: March 4

SEPTEMBER Closes August 5 OCTOBER Closes September 2

FEATURED EDITORIAL: FEATURED EDITORIAL: Validation; Viral Inactivation; Contract Manufacturing; Facilities Management; Assay Development; Documentation Management Technology Transfer; Site Expansion: UK SUPPLEMENT: BioPartnerships—Strategic PRIMER: Alliances to Accelerate Drug Development A Guide to Bioanalytical Advances (also appears in Pharmaceutical Executive) BONUS DISTRIBUTION: BONUS DISTRIBUTION: Biologics USA, Biotechnica BioPhex, ASME-BioProcess Technology Seminar ADDED VALUE PLACEMENT: ADDED VALUE PLACEMENT: Free 4C Product/Literature Release Advertiser Profiles, Autumn Advertising Package AD MATERIALS DUE: September 9 AD MATERIALS DUE: August 11 EDITORIAL MANUSCRIPT DUE: July 1 EDITORIAL MANUSCRIPT DUE: June 3 EDITORIAL CALENDAR 2005

MARCH Closes February 4 APRIL Closes March 4

FEATURED EDITORIAL: FEATURED EDITORIAL: Validation; Downstream Processing; Protein Expression; GMP; Q/A - Q/C; Raising Capital; RFID and the Supply Chain; Microarrays; Intellectual Property Global Manufacturing; Site Expansion: U.S.

PRIMER: BONUS DISTRIBUTION: A Guide to Validation PDA: SciTech Summit, INTERPHEX, BioAnalytica

ADDED VALUE: ADDED VALUE: Advertiser Profiles Full Page Advertisers Receive Interphex Exhibitor ProductBlast Literature Pack at INTERPHEX AD MATERIALS DUE: FREE Ad Laminate for Show Advertisers February 10 AD MATERIALS DUE: March 10 EDITORIAL MANUSCRIPT DUE: December 3 EDITORIAL MANUSCRIPT DUE: January 6

JULY Closes June 2 AUGUST Closes July 5

FEATURED EDITORIAL: FEATURED EDITORIAL: Formulation, Fill & Finish; Drug Delivery Systems; Scale-up Strategies; Analytical Methods; Generics Update; 21 CFR Part 11; Disposable Solutions; Site Expansion: Ireland FDA Inspections; Site Expansion: Scotland

ADDED VALUE: ADDED VALUE: Full Page Advertisers Receive 1/2 Off Exhibitor ProductBlast FREE Ad Performance Study Free 4C Product/Literature Release AD MATERIALS DUE: AD MATERIALS DUE: July 8 June 6 EDITORIAL MANUSCRIPT DUE: EDITORIAL MANUSCRIPT DUE: May 6 April 8

NOVEMBER Closes October 3 DECEMBER Closes November 4

FEATURED EDITORIAL: FEATURED EDITORIAL: Fermentation & Cell Culture; Scale-up Strategies; Security; Gene-based Drugs; Q/A - Q/C; GMP; Risk Management; Cost Containment Disposables; Trends

BONUS DISTRIBUTION: ADDED VALUE: AAPS Free 4C Product/Literature Release

ADDED VALUE: AD MATERIALS DUE: Full Page Advertisers Receive Interphex Exhibitor ProductBlast November 10 Literature Pack at AAPS, FREE Ad Laminate for Show Advertisers EDITORIAL MANUSCRIPT DUE: AD MATERIALS DUE: October 7 September 2 EDITORIAL MANUSCRIPT DUE: August 5 HOW MUCH TIME DO YOU TYPICALLY SPEND READING AN ISSUE? READER On average, readers spend forty-seven minutes with their issue PROFILE 11.2% One Hour or More 35.5% Forty-five Minutes to One Hour Deliver your message to 23.6% Thirty to Forty-five Minutes an active, loyal readership of 29.4% Less than Thirty Minutes decision-makers who 0.2% No Answer purchase products and services utilized throughout the biopharm enterprise.

With an average of 1.72 additional readers per copy the total audience is over 79,000 readers

HOW MANY OF THE LAST FOUR ISSUES OF BIOPHARM INTERNATIONAL HAVE YOU READ OR LOOKED THROUGH? More than three-quarters read three or four of four issues

61.9% Four of the last four issues 15.0% Three of the last four issues 12.4% Two of the last four issues 2.6% No answer 0.9% One of the last four issues 7.0% None of the last four issues 0.2% Recent subscriber, have not yet received four issues

WHAT ACTIONS HAVE YOU TAKEN IN RESPONSE TO ADS/ARTICLES? 93.7% have taken action in response to ads/articles in BioPharm International

Filed for future reference 74.5% Discussed with others 74.1% Routed an ad/article to another person 59.6% Incorporated new technique/medium/product 34.3% Recommended the purchase of a product/service 33.9% Called or wrote for more information 25.0% Purchased a product or service 21.5%

RESEARCH METHODOLOGY Questionnaires were emailed to a sample of 5,000 subscribers from BioPharm International’s subscriber file. Names were selected randomly on an nth name basis, in accordance with demographic breakouts, from active, qualified subscribers who have requested the publication. Proximity Research, an independent company specializing in research, circulation and email campaign management for b2b publishers, located in Cleveland Ohio, developed the electronic survey, deployed the emails and tabulated the results. The electronic questionnaire asked about reader preferences, the readability utility of BioPharm International and how readers used the information gained from reading BioPharm International in their job. Proximity sent an initial effort of 5,000 emails. 4,496 emails were delivered for a delivery rate of 89.8%. A total of 35 respondents opted-out and 594 emails bounced. The survey netted 428 responses for a response rate of 9.52%. An incentive of a randomly awarded digital camera was offered in both invitation emails. The level of confidence for this survey is (+/- 5%). WHICH OF THE FOLLOWING BEST DESCRIBES YOUR COMPANY’S PRIMARY BUSINESS? Respondent demographics closely match the BPA-audited demographics

70.6% BioPharm/Biotech/Pharma-related Industries^ 6.5% University/College/Research Institute 4.0% Contract Research & Analytical Services 3.0% Business/Investment/Legal Services 2.8% Architecture/Engineering/Construction 1.2% Government 9.6% Other 2.3% No Answer

TO THE BEST OF YOUR KNOWLEDGE WHAT IS YOUR COMPANY’S ANNUAL REVENUE? Respondents are employed by companies of all sizes

16.8% More than $1Billion 12.4% $500 - $999M 10.5% $100 - $500M 26.6% $1 - $99M 5.8% $250 - $999k 15.4% Less than $250k 12.4% No Answer

WHICH OF THE FOLLOWING BEST DESCRIBES YOUR PRIMARY JOB FUNCTION? Respondents are involved in a variety of job functions

23.1% QA/QC/Validation 16.8% Research 13.8% Process Development 7.7% Production Manufacturing 7.5% Corporate Management 6.3% Project Management 4.7% Technical Services/Analytical Support 4.4% Regulatory Affairs/Clinical Affairs 4.2% Lab Management 3.3% Business Advisor 3.0% Technology Transfer 2.3% Other 1.6% No Answer 1.2% Plant Engineering/Design

WHICH OF THE FOLLOWING BEST DESCRIBES YOUR JOB TITLE OR POSITION? More than half (54.2%) are in management positions

24.5% Manager 18.5% Scientist 16.6% Director 13.1% Corporate or Executive Management 8.9% Engineer 6.8% Staff/Associate 5.6% Other 4.2% Chemist 1.9% No Answer

^ BioPharm Related Industry: Biopharmaceutical, Biologics Process Development (23.8%), Conventional Pharma Manufacturing (19.6%), Biodiagnostic Process Development (0.9%), Biodiagnostic Manufacturing (2.3%), Biotherapeutic Discovery/Devlopment (2.1%), Biopharmaceutical Formulation/Delivery (5.8%), Transgenic Therapeutic Productions (0.2%), Specialty or Bulk Chemical Manufacturing, Bulk Products, Raw material Producers (2.8%), Biotechnology/Biopharm Research (12.1%) 54% ARE INVOLVED IN PURCHASING PURCHASE LABORATORY PRODUCTS & EQUIPMENT

AUTHORITY Analytical Laboratory Equipment 34.3% Calibration Standards 25.0% Glassware & Pipettes 21.5% Laboratory Appliances 21.3% Cleaning Equipment, Autoclaves & Ovens 19.2% Incubators 18.7% Liquid Handling Equipment & Pumps 18.0% Electrophoresis Products & Apparatus 17.8% Spectroscopy Equipment 17.1% Safety 15.2% Measuring Devices 14.3% Lyophilizers 12.9% Homogenizers 10.7% DNA & RNA Analysis 9.1% Nuclear & Luninescence Instrumentation & Accessoris 6.3% Combinatorial Chemistry & High-Throughput Screening 5.1%

51.2% ARE INVOLVED IN PURCHASING BIOCHEMICALS, CHEMICALS AND RAW MATERIALS

Reagents 26.6% Chemicals 26.4% Raw Materials 25.5% Solvents, Detergents & Buffers 22.0% Biochemicals & Organic Raw Materials 21.7% Proteins & Peptides 20.6% Antibodies & Antigens 19.4% Contract Consulting & Pharmaceutical Services 17.5% Specialty or Bulk Raw Materials 17.5% Enzymes 16.1% Media & Sera 14.7% Viruses & Bacteria 10.3% Enzymes 9.8%

38.3% ARE INVOLVED IN PURCHASING SEPARATION & PURIFICATION PRODUCTS & SERVICES

Processing Equipment 18.7% Bio Reactors/Fermentors 16.1% Disposable Processing Equipment 14.3% Fill & Finish 13.1% Packaging & Labeling Equipment 11.7% Storage Equipment & Distribution 11.4%

32% ARE INVOLVED IN PURCHASING MANUFACTURING / PROCESSING EQUIPMENT & PRODUCTS

Chromatographic Equipment 25.7% Separation & Purification Products 23.8% Filters, Membranes & Air Purifiers 22.2% Centrifuge Products 20.1% Magnetic Sorting Systems & Particles 6.1% 36.2% ARE INVOLVED IN PURCHASING ON AVERAGE READERS WORK OUTSOURCED SERVICES & PHARMA SERVICES FOR COMPANIES INVESTING $302.9 MILLION IN R&D

Contract Manufacturing 17.5% 6.5% More Than Analytical Methods & Validation Services 17.3% $1 Billion Contract Laboratory 16.8% 5.6% $500 - $999M Biopharm Development & Scale-Up 15.7% 12.4% $100 - $500M Contract Consulting 13.1% 25.5% $1 - $99M Contract Research 12.1% 11.0% $250 - $999k Drug Discovery & Lead Optimization 7.2% 21.5% Less than $250k 17.5% No Answer

27.6% ARE INVOLVED IN PURCHASING COMPUTER SYSTEMS

Software Systems & Accessories 15.4% Validation Software 13.1% Data Management Software 12.4% ARE YOU INVOLVED IN Hardware Systems & Accessories 11.4% Documentation Software 11.0% RESEARCH & DEVELOPMENT? Bioprocess Control Software 8.6% Automation & Robotics 8.4% Batch Control Software 6.1%

58.6% Yes 39.3% No 2.1% No Answer 26.4% ARE INVOLVED IN PURCHASING PRODUCTS FOR CONTROLLED ENVIRONMENTS

Clean Room Supplies 13.1% Clean Room Garments 11.9% Clean Room Components & Design 11.0% Hoods & Ventilation 11.0% Cleaning Validation Assays 9.1% Air Samplers 9.1% ON AVERAGE, 69.7% OF BIOPHARM READERS’ RESEARCH IS GEARED TOWARDS COMMERCIAL 24.1% ARE INVOLVED IN PURCHASING PRODUCT DEVELOPMENT FERMENTATION AND CELL CULTURE PRODUCTS & EQUIPMENT

Cell Culture 16.4% 29.1% 100% Cell Culture Equipment 16.4% 25.1% 75 - 99% Fermentation 14.3% 19.1% 50 - 74% Fermentation & Cell Culture Products 9.6% 12.0% 25 -49% Cryogenics 9.6% 13.5% Less than 25% Plant Transgenics 3.7% 1.2% No Answer

14.73% ARE INVOLVED IN PURCHASING OF ENGINEERING FACILITIES SERVICES

Utilities & Waste Management 11.0% Engineering & Facilities Services 10.7% Facilities Design & Construction 8.4% WHICH OF THE FOLLOWING PUBLICATIONS READER DO YOU SUBSCRIBE TO, OR RECEIVE PERSONALLY ADDRESSED TO YOU? Nearly one-third of BioPharm International readers PROFILE cannot be reached in ANY of these publications

None 29.4% Readers rely on BioPharm Genetic Engineering News 28.7% as the information leader BioProcess International 28.3% Contract Pharma 26.4% because they feel it BioTechniques 25.9% provides actionable Bioprocessing Journal 15.2% Bio IT World 14.3% information that keeps Nature Biotechnology 11.9% them current and helps Bioscience 11.2% them in their job.

IF YOU COULD ONLY RECEIVE ONE PUBLICATION, WHICH WOULD YOU CHOOSE?

BioPharm International 55.1% Genetic Engineering News 9.1% Nature Biotechnology 8.2% Contract Pharma 6.3% BioProcess International 5.4% No Answer 4.4% Bioscience 4.0% BioTechniques 4.2% Bioprocessing Journal 1.9% Bio IT World 1.4%

PLEASE INDICATE ALL AREAS YOU ARE INTERESTED IN READING ABOUT IN BIOPHARM INTERNATIONAL.

Biochemicals, Chemicals, Raw Materials 76.2% Laboratory Products & Equipment 72.0% Contract Consulting & Pharmaceutical Services 61.4% Separation & Purification 52.3% Computer Systems 52.3% Processing Equipment/Manufacturing Systems 50.0% Controlled Environments 43.7% Fermentation & Cell Culture 39.0% Engineering Facilities 28.3%

PLEASE DESCRIBE WHY YOU READ BIOPHARM INTERNATIONAL.

It keeps me up-to-date on the latest advances and industry trends 83.6% It gives me information that helps me do my job better 60.0% It provides technically accurate information 48.1% It helps me identify potential suppliers/ 41.4% resources and make purchasing decisions I am interested in international growth and trends 40.0% No Answer 0.5% STANDARD TERMS AND CONDITIONS FOR ADVERTISING The following terms and conditions (the “Standard Terms”) shall be incorporated by reference into all Insertion Orders submitted to Advanstar Communications Inc. (“Publisher”) by Advertiser or its advertising agency: A Invoices are rendered at date of publication. B Publisher holds the Advertiser and its advertising agency jointly responsible for paying all duly authorized advertising inserted in or attached to BioPharm International. All overdue payments will be reinvoiced directly to the Advertiser, who will be held fully responsible for payment. C Terms: Invoices are rendered on the publication date of each issue and are due upon receipt. Agency commission will be disallowed on all overdue invoices. In the event Advertiser’s account is placed for collection, Advertiser and agency agree to pay Publisher for all reasonable collection costs and/or attorneys’ fees incurred. Advertiser and agency also agree to pay finance charges on the unpaid account balance at the rate of 1-1/2% per month or the maximum permitted by law. D Publisher will not be bound by any terms, conditions or provisions appearing on insertion orders or copy instructions which conflict with provisions of these Standard Terms, includ- ing, without limitation, sequential liability statements from advertising agencies. In the event of any inconsistency between an insertion order and/or copy instructions and these Standard Terms, the Standard Terms shall control. E All advertisements are accepted and published by the Publisher on the representation that the agency and/or Advertiser are properly authorized to publish the entire contents and subject matter thereof. F Advertiser hereby grants Publisher the right and license to use, reproduce, transmit, and distribute all creative materials supplied by or on behalf of Advertiser, including without lim- itation, all text, graphics, illustrations and photographs (the “Creative”). Advertiser represents and warrants that: (i) it has all the necessary rights in the Creative; (ii) the Creative does not violate any applicable law or regulation; and (iii) the Creative does not violate or infringe upon any third party right in any manner or contain any material or information that is defamato- ry, libelous, slanderous, that violates any person’s right of publicity, privacy or personality, or may otherwise result in any tort, injury, damage or harm to any person. Advertiser acknowl- edges that Publisher is relying on the foregoing representations and warranties. Advertiser agrees to indemnify, defend and hold Publisher and its affiliates, and their respective officers, directors and employees, harmless from and against any and all expenses and losses of any kind (including reasonable attorneys’ fees and costs) incurred based upon a breach of any of the foregoing representations and warranties or in connection with any claim arising from or related to any advertisement supplied by Advertiser or its agents and run by Publisher. G Publisher reserves the right to reject any advertising which Publisher feels is not in keeping with the publication’s standards or for any other reason, even if the advertising has been published previously by Publisher. H Publisher shall not be liable for any omitted, misplaced, or mispositioned advertisements. I All orders are accepted by Publisher subject to change in rate upon notice from Publisher. J Orders may be cancelled within ten (10) business days of the effective date of a change of rates without incurring a shortrate adjustment, provided the Advertiser’s contract rate has been earned as of the date of cancellation. K An order may be cancelled without liability up to thirty (30) days prior to the issue’s ad close date. Publisher reserves the right to demand payment for orders cancelled less than thir- ty (30) days prior to ad close, regardless of the date of ad placement. L A 1/4 page ad is the minimum rate holder. M Advertiser will be shortrated if, within a 12-month period from the date of the first insertion, Advertiser does not use the amount of space upon which its billings has been based. Advertiser will be rebated if, within a 12-month period from the date of the first insertion, Advertiser has used sufficient additional space to warrant a lower rate than that at which it has been billed. N Costs incurred by Publisher for production work on advertisements will be charged to the Advertiser regardless of whether or not the ad runs. Advertiser will be charged for any art- work, separations, halftone, shipping, or typography provided by Publisher. O In the event a change of copy is not received by Publisher by the publication’s ad closing date, the copy run in the previous issue of the publication will be inserted. P Publisher will hold Advertiser’s materials for a maximum of one year from last issue date. It is the responsibility of the Advertiser to arrange for the disposition of artwork, proofs or digital materials prior to that time, otherwise materials will be destroyed. All requests must be submitted in writing. Q Publisher will not be held responsible for consequential costs or other damages due to loss or damage of digital ad materials, art, proofs or transparencies. R Reader response inquiries are provided as a service. Publisher disclaims all liability and responsibility for inaccuracies. S Under no circumstances shall Publisher be liable for any indirect, incidental, special or consequential damages (including, without limitation, loss of profit or impairment of goodwill) of any Advertiser. Under no circumstances shall Publisher’s direct or indirect liability to any advertising agency or Advertiser exceed the invoiced cost of the advertisement. Notwithstanding the foregoing, Publisher shall have no liability for (i) any failure or delay resulting from conditions beyond Publisher’s control; or (ii) errors in content or omissions in any creative or advertising materials provided by Advertiser. T These Standard Terms, together with insertion orders submitted by Advertiser, (i) shall be governed by and construed in accordance with the laws of the State of New York and the United States, without giving effect to principles of conflicts law; (ii) may be amended only by written agreement executed by an authorized representative of each party; and (iii) con- stitute the complete and entire expression of the agreement between the parties, and shall supersede any and all other agreements regarding the subject matter hereof, whether written or oral, between the parties. Failure by either party to enforce any provision of these Standard Terms shall not be deemed a waiver of future enforcement of that or any other provision. Advertiser may not resell, assign, or transfer any of its rights hereunder.

COMMISSION Accredited advertising agencies receive a 15% commission provided invoices are paid within 30 days. Production charges are not subject to agency commission. Contact us at 1-800-933-5354